Science1 publisher3 min readPublished
Revolution Medicines' expanded access program for Rasonque closed immediately on FDA approval, leaving patients still mid-application to wait on insurers whose paperwork moves slower than metastatic pancreatic cancer.
The Scientist · Science desk
Compiled by The ScientistSomething wrong?How this is made
Nearly doubling median overall survival is the result that put Rasonque on families' radar, and STAT reports it as a ratio [6]. A doubled median says where the middle patient in a trial ended up, but the account does not supply the actual months either group received, so the figure a family most needs, what a four-week wait for a prior authorization costs them, is missing. STAT calls the drug the only major breakthrough in pancreatic cancer in more than four decades [17], which describes the field's history rather than anyone's calendar.
The closure follows from the design of expanded access. The program existed because the drug was not yet approved, and approval removed its premise [2]. Payment did not arrive on the same day. Solano and the cancer specialists STAT interviewed describe commercial coverage as often unavailable for weeks or months while payers work through the technical steps of covering a new medication [7]. The FDA starts one clock, insurers run the other, and patients mid-application sit in the gap.
The Medicare denial in the story traces to a clerical listing issue, not a clinical judgment. Loaiza-Bonilla, who co-founded the cancer tech company Massive Bio and practices at St. Luke's University Health Network in Pennsylvania, said the justification he received was nonclinical and made no sense to him [10]. The reversal followed his post, but the reporting shows only that the two events occurred in sequence, without demonstrating cause, and the nearest thing to a comparison group in the reporting cuts against the tidy reading: other St. Luke's patients in the same position had heard nothing back from their insurers, he told STAT [12].
Timescale is what makes that interval matter in one of the deadliest cancer types [16]. Juan Solano was diagnosed at stage 3 in January 2025, had the tumor removed in an Appleby procedure, and finished FOLFIRINOX [13]. His team believed he was disease-free in November 2025, and inside two months he had stage 4 disease [14]. A BridgeBio Oncology Therapeutics drug, tested in a trial nearly four hours from home at Fred Hutchinson Cancer Center in Seattle, slowed the cancer before it expanded through his liver, bile duct, and peritoneum [15]. Diagnosis to the August 2026 approval that closed the program is about 19 months [18][19], and in that span the disease had already outrun surgery and an experimental agent.
Scale is what the reporting does not establish. The reporting carries no comment from Revolution Medicines on why the program closed at approval or whether any bridge supply was offered, and no count of the patients who were mid-application when it did [20]. Fleshman names the exposed group precisely without sizing it [8]. The mechanism is documented, but the denominator is missing. That is enough to justify planning a bridge before the next approval of this kind, though it does not establish how many people this one stranded.
Ranked by verification strength, evidence, and original report placement.
The Food and Drug Administration approved a new pancreatic cancer drug called Rasonque "last month", according to a STAT report published 2026-09-08.
The expanded access program run by Rasonque's maker, Revolution Medicines, which had been set up to provide the drug before regulatory approval, closed immediately when the approval came through.
Kelsey Solano, a critical care nurse in Washington state, was going through the expanded access program hoping to obtain the drug for her husband Juan, who has metastatic pancreatic cancer.
Kelsey Solano and her husband were in the middle of finishing paperwork to join Revolution Medicines' early access program when the approval landed, and Solano said she felt "a pit in her stomach" because the program immediately closed.
For families who had already been counting on expanded access, getting the drug quickly became far more difficult after the approval.
Approvals generally improve access to drugs that previously were available only on limited programs or in clinical trials.
Follow any of these and your For You feed starts watching them — no settings page required.
Evidence-backed comparisons of source perspectives and observed adoption signals. Read the methodology
Which Builder, Operator, and Investor concerns the observed source mix emphasized—not a truth score.
Evidence, demonstrated adoption, hype gap, incentives, and confidence are assessed independently, each on its own current evidence. How these are measured.
First-hand, one desk
The specifics are strongest where a reporter can see them: a denial letter quoted verbatim, a named oncologist describing the reversal that followed his public post, PanCAN's chief executive confirming other patients are stuck, and a Revolution Medicines executive on the record about (ON)PATH. Absent is anyone on the paying side of the transaction, and the drug's near-doubling of median survival arrives with no trial or label reference attached to it.
Named cases, no denominator
Four access events are pinned down: the program closing on approval day, one Medicare denial reversed after publicity, unanswered requests for other St. Luke's patients, and Aetna unable to open a request for a drug missing from its formulary system. PanCAN says more patients are caught the same way and supplies no count; neither does Revolution Medicines, so the breadth of the gap is asserted rather than measured.
Scope wider than the count
Each step of the mechanism is documented where the reporting touches it, while the language around it runs ahead of what is shown: "nearly double median overall survival" and "sole major breakthrough in more than four decades" are stated without sourcing, and "some patients" carries weight a number would carry better. The overstatement is one of scale, not of the harm itself.
Every stake pointed one way
Every person quoted here has a stake in faster commercial access. The wife of a patient rolling off a trial, an advocacy organization whose constituency is pancreatic cancer patients, an oncologist who co-founded a cancer technology company, and the manufacturer's commercialization chief describing the program that softens the transition all sit on the same side of the question. STAT names each affiliation; missing is any voice with the opposite interest, since neither insurers nor PBMs explain why loading a new drug takes as long as it does.
Trust the episodes, not the scale
The individual episodes are specific and attributed to people who lived through them, which is enough to believe them. What the account does not settle is the share of Rasonque patients who hit this gap, whether closing early access at approval was the company's choice or a condition attached to it, and how long payer loading normally takes.
invest
A pancreatic pill proves pan-RAS is druggable. Lung and colon will price the claim1 publisher
leadership
Revolution Medicines' RAS glue needed fourteen years from funded idea to FDA approval1 publisher
science
Software picks the 34 neoantigens in Moderna and Merck's cancer vaccine1 publisher
product
A blood-draw robot clears the FDA at 1m49s a stick. The missing number is per supervisor1 publisher
Publishers with included, body-backed reporting in this cluster.
1 article · September 8, 2026